EXPLANATORY NOTE: [**] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL ANDLicense, Supply and Distribution Agreement • June 21st, 2019 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • Delaware
THIS LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT is made as of March 6, 2019 (the “Effective Date”), by and between ELITE PHARMACEUTICALS, INC. a Nevada corporation and ELITE LABORATORIES, INC., Delaware corporation located at 165 Ludlow Avenue, Northvale, New Jersey 07647 (collectively, “ELITE”), and LANNETT COMPANY, INC., USA, a Delaware corporation located at 9000 State Road, Philadelphia, PA 19136 and/or its Affiliates (“LANNETT”).
EXPLANATORY NOTE: [**] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL ANDDevelopment Agreement • June 21st, 2019 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • New Jersey
This DEVELOPMENT AGREEMENT (the “Agreement”), dated December 3, 2018 (the “Effective Date”) between Mikah Pharma LLC, 20 Kilmer Drive, Hillsborough, NJ 08844 (“Mikah”) and Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.), organized under the laws of the State of Delaware, with offices at 165 Ludlow Avenue, Northvale, New Jersey, USA (“Elite”); Mikah and Elite may sometimes hereinafter be referred to as a “Party” or collectively as the “Parties”.
